Government and Gennova negotiating a competitive price for mRNA vaccine

30 Jun 2022 , 12:28 PM

The Covid-19 vaccine from Gennova Biopharmaceuticals would be reasonably priced, according to the company, which acquired emergency use authorization (EUA) from India’s medicines regulator on Wednesday. The first domestically produced mRNA Covid vaccination is offered by Gennova, a company based in Pune.

The creation of the vaccine had received government assistance. Government price negotiations are still going on, according to chief operating officer Samit Mehta.

“In terms of pricing, there is currently continuous conversation with the government on this subject. We will be considerably more competitive than our international competitors on this platform, I can guarantee with certainty, he added during a press conference.

Gennova has manufactured 7 million doses since receiving the manufacturing-at-risk permission. They have all been approved for distribution by the company’s internal quality control and the government’s nodal Central Drugs Laboratory at Kasauli in Himachal Pradesh, according to him. “So as in, we should be able to send this right away as the orders come through,” he said.

Since the majority of people have already received both doses of the Covid vaccination, Mehta stated that the potential market for the vaccine would be for booster shots. The next step, according to him, would be to position the vaccine for use in youngsters.

Since the start of classes again, several youngsters have become ill, he claimed. Therefore, I believe that (vaccinating children) will be the right course of action. To export the novel vaccine, the business intends to take advantage of Emcure Pharmaceuticals’ extensive global network.

Mehta reported that questions for Gennova had already come from Southeast Asia and Latin America. The records and the most recent update of the EUA in India have previously been submitted to the regulatory agency by a country in Latin America, he continued.

According to him, the parent business Emcure has operations in more than 70 nations. “The emergency use authorization has now been issued to the entire network,” he continued, “so that any requests that may come in will be correctly routed.”

Mehta added that a considerable sum had been spent on the creation of the vaccine. He said that the business had been developing an mRNA platform for more than four years.